The estimated Net Worth of Dell Faulkingham is at least $1.62 Миллион dollars as of 28 February 2022. Mr. Faulkingham owns over 13,184 units of Akebia Therapeutics stock worth over $250,331 and over the last 5 years he sold AKBA stock worth over $129,074. In addition, he makes $1,241,700 as Senior Vice President и Chief Commercial Officer at Akebia Therapeutics.
Dell has made over 4 trades of the Akebia Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 13,184 units of AKBA stock worth $28,477 on 28 February 2022.
The largest trade he's ever made was selling 13,184 units of Akebia Therapeutics stock on 28 February 2022 worth over $28,477. On average, Dell trades about 3,902 units every 91 days since 2019. As of 28 February 2022 he still owns at least 173,841 units of Akebia Therapeutics stock.
You can see the complete history of Mr. Faulkingham stock trades at the bottom of the page.
Dell Faulkingham is Senior Vice President, Chief Commercial Officer of the Company. Prior to joining Akebia, from August 2018 through April 2019, Mr. Faulkingham was Senior Vice President and Head, United States Multiple Sclerosis, or M.S., Franchise, at Biogen, Inc., or Biogen, a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, where he was responsible for developing and leading execution of the long-term franchise strategy across the U.S. organization. Previously, he held a number of key roles at Biogen beginning in 2010, including Vice President, Head of U.S. M.S. Marketing and Field Operations from May 2017 to August 2018, Vice President, Head of U.S. M.S. Marketing from September 2016 to May 2017, Vice President, Global Asset Executive, Tecfidera from October 2015 to September 2016, Senior Director, Global Marketing Lead, Tecfidera from January 2015 to October 2015, and Senior Director, U.S. Marketing Lead, Tecfidera and TYSABRI from August 2013 to January 2015. Prior to that, he worked in sales and marketing for Forest Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. from 1998 to 2010. He holds a B.S. in Biology from the University of Georgia.
As the Senior Vice President и Chief Commercial Officer of Akebia Therapeutics, the total compensation of Dell Faulkingham at Akebia Therapeutics is $1,241,700. There are 3 executives at Akebia Therapeutics getting paid more, with John Butler having the highest compensation of $4,316,960.
Dell Faulkingham is 47, he's been the Senior Vice President и Chief Commercial Officer of Akebia Therapeutics since 2019. There are 15 older and 3 younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.
Dell's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter и Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Akebia Therapeutics executives and other stock owners filed with the SEC include: